surmount-1 tirzepatide obesity nejm 2022 weight loss percent 📊 Semaglutide 2.4mg: −13.7% (SURMOUNT-5 head-to-head), 📊 15mg: −20.2% weight loss (same trial, 2025), 📊 Retatrutide 12mg: −28.7% weight loss (TRIUMPH-4, Phase 3, Dec Three-year study of tirzepatide shows

Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial - Springer Nature Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide - The Journal of Clinical Endocrinology & Metabolism Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist - JCI Insight Fibre intake for optimal health: how can healthcare professionals support people to reach dietary recommendations

More gets directed toward muscle glycogen replenishment and less toward fat storage

In addition, prevention and treatment of hypoglycemia with excessive carbohydrates also contribute to weight gain

It's the most common and practical route, and once you've done it a few times it becomes second nature